You are here

Our science / Clinical Trials / Find a Trial / NCT03643211

Xeljanz Special Investigation for Long-term Use in UC Patients

Back to Search Print Save as PDF Bookmark Trial

NCT03643211

Last updated on August 24, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Local Country Office
Tokyo, , Japan
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ulcerative Colitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with ulcerative colitis treated with XELJANZ

- Patients naive to XELJANZ in the treatment of ulcerative colitis

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- None

NCT03643211
Pfizer
Recruiting
Xeljanz Special Investigation for Long-term Use in UC Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Ulcerative Colitis
Xeljanz Special Investigation for Long-term Use in UC Patients
NCT03643211
All Genders
20+
Years
Tokyo,
Ulcerative Colitis
PF-06687234 add on therapy in active UC subjects - BUILD UC
NCT03269695
All Genders
18+
Years
Multiple Sites
Ulcerative Colitis
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission
NCT03281304
All Genders
18+
Years
Multiple Sites
Ulcerative Colitis
Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
NCT02958865
All Genders
18+
Years
Multiple Sites
Xeljanz Special Investigation for Long-term Use in UC Patients
Xeljanz® Tablets 5 Mg Special Investigation (Investigation Of Long-term Use In Patients With Ulcerative Colitis)
Secondary data collection study: safety and effectiveness of Xeljanz in UC patients under Japanese medical practice
This investigation aims to examine the safety and effectiveness of Xeljanz in post-marketing clinical settings when it is administered chronically to patients with ulcerative colitis, based on the approval conditions.
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
UC patients who were confirmed to have received Xeljanz after the approval date of dosage and administration of Xeljanz for UC patients
Ulcerative Colitis
Not Provided
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
500
Same as current
February 25, 2022
February 25, 2022   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with ulcerative colitis treated with XELJANZ
  • Patients naive to XELJANZ in the treatment of ulcerative colitis

Exclusion Criteria:

- None
Sexes Eligible for Study: All
20 Years and older   (Adult, Older Adult)
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Japan
 
 
NCT03643211
A3921248
Not Provided
Not Provided
Plan to Share IPD: No
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
August 2018

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now